Especially one analyst remained skeptical towards Ambu’s praisefor its growth hope, the colonoscope SC210. “It’s okay to be optimistic but you still have to give the market correct information,” says the Carnegie analyst who was not particularly surprised by Ambu’s recent adjustment of the financial outlook and following share price decline.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.